- Investing Ideas
- /
- U.S. Biotech Stocks
U.S. Biotech Stocks
Results
438
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
438 companies
Johnson & Johnson
Market Cap: US$467.0b
Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
JNJ
US$194.39
7D
4.5%
1Y
26.9%
AbbVie
Market Cap: US$398.0b
A research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.
ABBV
US$233.23
7D
7.6%
1Y
36.9%
Merck
Market Cap: US$225.7b
Operates as a healthcare company worldwide.
MRK
US$91.45
7D
8.4%
1Y
-7.2%
Thermo Fisher Scientific
Market Cap: US$220.3b
Provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.
TMO
US$588.02
7D
3.6%
1Y
8.5%
Amgen
Market Cap: US$182.2b
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
AMGN
US$336.28
7D
5.1%
1Y
11.6%
Gilead Sciences
Market Cap: US$152.1b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$123.40
7D
0.7%
1Y
33.2%
Pfizer
Market Cap: US$145.0b
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
PFE
US$25.87
7D
5.1%
1Y
-3.2%
Vertex Pharmaceuticals
Market Cap: US$108.9b
A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
VRTX
US$434.19
7D
4.1%
1Y
-12.2%
Bristol-Myers Squibb
Market Cap: US$99.2b
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
BMY
US$49.08
7D
5.6%
1Y
-16.0%
Regeneron Pharmaceuticals
Market Cap: US$69.2b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
REGN
US$681.72
7D
5.8%
1Y
-15.2%
Alnylam Pharmaceuticals
Market Cap: US$59.7b
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
ALNY
US$452.74
7D
4.2%
1Y
71.1%
Zoetis
Market Cap: US$52.9b
Engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally.
ZTS
US$121.25
7D
0.6%
1Y
-31.5%
Insmed
Market Cap: US$41.3b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$194.39
7D
4.0%
1Y
175.3%
BeOne Medicines
Market Cap: US$38.0b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$377.47
7D
17.4%
1Y
93.1%
Teva Pharmaceutical Industries
Market Cap: US$28.8b
Develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
TEVA
US$25.83
7D
5.0%
1Y
52.5%
BioNTech
Market Cap: US$26.9b
A biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.
BNTX
US$111.70
7D
8.1%
1Y
7.9%
Biogen
Market Cap: US$23.7b
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
BIIB
US$161.48
7D
3.0%
1Y
-2.1%
Royalty Pharma
Market Cap: US$22.5b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$39.59
7D
-2.1%
1Y
53.2%
Incyte
Market Cap: US$21.2b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$108.26
7D
2.4%
1Y
34.5%
United Therapeutics
Market Cap: US$19.8b
A biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
UTHR
US$461.54
7D
3.1%
1Y
15.3%
Illumina
Market Cap: US$18.7b
Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
ILMN
US$121.98
7D
-0.4%
1Y
-16.5%
Neurocrine Biosciences
Market Cap: US$14.7b
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
NBIX
US$146.85
7D
-4.5%
1Y
17.0%
Summit Therapeutics
Market Cap: US$14.3b
A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
SMMT
US$18.83
7D
4.2%
1Y
-3.3%
Viatris
Market Cap: US$12.9b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$11.01
7D
2.4%
1Y
-15.3%
Exact Sciences
Market Cap: US$12.8b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS
US$68.37
7D
-1.8%
1Y
34.8%
Tempus AI
Market Cap: US$12.7b
Operates as a healthcare technology company.
TEM
US$71.10
7D
-13.6%
1Y
4.4%
ICON
Market Cap: US$12.5b
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
ICLR
US$163.42
7D
-0.2%
1Y
-19.9%
Revolution Medicines
Market Cap: US$12.4b
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
RVMD
US$65.83
7D
10.9%
1Y
13.2%
Madrigal Pharmaceuticals
Market Cap: US$12.3b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$528.94
7D
11.2%
1Y
67.8%
Ionis Pharmaceuticals
Market Cap: US$11.7b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$72.67
7D
-2.7%
1Y
92.4%
Exelixis
Market Cap: US$11.6b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$43.59
7D
8.0%
1Y
23.9%
Elanco Animal Health
Market Cap: US$11.4b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$22.05
7D
2.1%
1Y
55.4%
Revvity
Market Cap: US$10.7b
Provides health sciences solutions, technologies, and services.
RVTY
US$94.13
7D
1.7%
1Y
-21.4%
BioMarin Pharmaceutical
Market Cap: US$10.6b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$55.32
7D
4.8%
1Y
-17.0%
Moderna
Market Cap: US$10.3b
A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
MRNA
US$26.71
7D
13.4%
1Y
-36.6%
Qiagen
Market Cap: US$9.6b
Provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.
QGEN
US$44.53
7D
1.1%
1Y
1.6%